Relevant events during the quarter
No material updates were provided in the Q3 report. During the quarter Nanexa announced the initial PK data of the NEX-20 Ph 1 study, where it confirmed the controlled release of lenalidomide with the PharmaShell technology previously seen in preclinical studies. In October Nanexa announced the completion of the study, confirming the PK results with no unexpected adverse events that could compromise the use of NEX-20 aside from localised dose-dependent skin reactions (ranging from mild to moderate). A new formulation is currently being developed to solve these issues. Regarding NEX-22, advancements during the quarter include results from a preclinical study in minipigs showing a long release profile of liraglutide. Nanexa is working to finalise the CTA for the first clinical study (Ph 1 trial) in type 2 diabetes. The study is expected to start in Q1'24. Regarding the partnered projects, Nanexa announced in the report that the Novo Nordisk collaboration continues to advance positively, as well as it has seen very interesting results in other partner-driven evaluations with other world-leading pharmaceutical companies. During the quarter Nanexa announced carrying out a right issue of approximately SEK 121m. The company announced in October it managed to secure ~62% of the offered volume, totalling SEK 75m (see note here).
Aktuellt
SENASTE
